Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
143.66 USD   +0.79%
10:47aPfizer, BioNTech Reportedly in Talks with EU Over Reducing COVID-19 Vaccine Orders
MT
10:21aOmicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDC
RE
09:47aEU Mulls Changes to COVID-19 Vaccine Deal With BioNTech, Pfizer
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AGC Biologics Partners with BioNTech SE to Further Supply Plasmid DNA Starting Material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility

06/07/2021 | 10:06am EST

AGC Biologics has announced its partnership with BioNTech SE to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC's Heidelberg, Germany facility. AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech's mRNA-based vaccine manufacturing process. AGC Biologics' Heidelberg facility has over 20 years of experience delivering a very wide range of microbial programs for customers.

In addition, the site is AGC's Center of Excellence for Plasmid DNA (pDNA) production, as part of their end-to-end Cell and Gene Therapy offering.


© S&P Capital IQ 2021
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 0.79% 143.66 Delayed Quote.-5.11%
All news about BIONTECH SE
10:47aPfizer, BioNTech Reportedly in Talks with EU Over Reducing COVID-19 Vaccine Orders
MT
10:21aOmicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDC
RE
09:47aEU Mulls Changes to COVID-19 Vaccine Deal With BioNTech, Pfizer
MT
08:35aEU Might Buy Fewer Vaccine Doses From Pfizer, BioNTech for Higher Price, Reuters Report..
DJ
07:54aExclusive-EU may pay more for Pfizer COVID shots in return for lower volume
RE
01/26US CDC Continues Inquiry Into Potential Stroke Link from Pfizer, BioNTech Booster Shot
MT
01/26FDA advisers back the same COVID vaccine for initial shots, boosters
RE
01/26Novavax needs 6 months to produce annual COVID shots that match new variants
RE
01/26U.S. CDC still looking at potential stroke risk from Pfizer bivalent COVID shot
RE
01/25Updated COVID vaccines prevented illness from latest variants -CDC
RE
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2022 16 406 M 17 809 M 17 809 M
Net income 2022 8 721 M 9 467 M 9 467 M
Net cash 2022 15 913 M 17 274 M 17 274 M
P/E ratio 2022 3,84x
Yield 2022 -
Capitalization 32 161 M 34 912 M 34 912 M
EV / Sales 2022 0,99x
EV / Sales 2023 1,06x
Nbr of Employees 4 000
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 132,34 €
Average target price 197,96 €
Spread / Average Target 49,6%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-5.11%34 640
VERTEX PHARMACEUTICALS11.16%82 403
REGENERON PHARMACEUTICALS, INC.2.88%79 279
WUXI APPTEC CO., LTD.20.37%42 325
BEIGENE, LTD.18.96%27 198
GENMAB A/S-9.83%25 315